Mucomixx est un complément alimentaire contenant du Levilactobacillus brevis* DSM27961 pour l’hygiène buccale.
Ingrédients
Mucomixx contient au moins 1 milliard de Levilactobacillus brevis DSM 27961 par pastille. La boite contient 20 pastilles dans un flacon pratique.
*Lactobacillus brevis a été reclassé en Levilactobacillus brevis selon une étude publiée par Zheng et ses collègues (Zheng et al., Int J Syst Evol Microbiol 2020 Apr 15. doi : 10.1099/ijsem.0.004107)
Actualités et événements
Mucomixx at the IV ATASIO National Congress
At the beginning of February the IV National Congress ATASIO (Academy of Advanced Technologies in Oral Hygiene Sciences) was held in Rome at the Department of Odontostomatological Sciences
The role of inflammation and genetics in periodontal disease
Loos, B. G. & Van Dyke, T. E. Abstract Patients with periodontitis show inflammatory destruction of the supporting tissues around the teeth. Loss of connective tissue and collagen
Lactobacillus brevis CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study.
De Sanctis, V., Belgioia, L., Cante, D., La Porta, M. R., Caspiani, O., Guarnaccia, R., et al. Abstract BACKGROUND - Oropharyngeal mucositis occurs in virtually all patients with
Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation
Sharma, A., Rath, G. K., Chaudhary, S. P., Thakar, A., Mohanti, B. K., & Bahadur, S. Background Oral mucositis is a common inflammatory complication in patients undergoing high-dose
A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
Giammarco, S., Chiusolo, P., Di Giovanni, A., Metafuni, E., Sica, S., Iavarone, F., et al. Abstract Treatment-induced oral mucositis (OM) is a pathological process characterized by mucosal damage,
